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Serotonin has various functions throughout the body and directly effects many neurological 
diseases/disorders, like depression, that are linked to the dysregulation of serotonin. 
Triptans are indole containing drugs that bind to a subset of serotonin receptors (5-HT1B 
and 5-HT1D) and are used to treat migraines. In this project, the synthesis of an indole 
intermediate is attempted. Ideally, an azobenzene would have been added to the 5th 
position (replacing the primary amine). Azobenzenes are compounds composed of 2 
benzene rings connected by a nitrogen-nitrogen double bond that can switch between cis 
and trans conformations by absorbing different wavelengths of light. The transformation 
of the indole intermediate into a photoswitch is believed to be possible based on the 
structures of triptans. The first two steps of the synthesis of the indole intermediate were 
completed and product was produced with 72.9% yield. The column conditions that 
provided the best separation was determined to be 5% methanol in DCM with 
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Serotonin, or 5-hydroxytryptamine (5-HT) (Figure 1), is a neurotransmitter that has 
a variety of functions throughout the body. It is present in the heart, the respiratory system, 
the intestines, the central nervous system, and in the reproductive organs1. Some of its 
functions are regulating heart rate, platelet aggregation, mood, sleep, etc. The dysregulation 
of serotonin in the body has been linked to diseases such as irritable bowel syndrome (IBS), 
nausea and emesisi, pulmonary arterial hypertensionii (PAH), sudden infant death 
syndrome (SIDS), mood disorders, pain disorders, and preeclampsia. Since the same 
serotonin receptors are in different parts of the body and regulate different biological 
processes, there has been a longstanding need to design drugs to target the specific receptor 
in the correct tissue that is responsible for the diseases. To address this challenge, we must 
talk about the structures of the serotonin receptors. 
 
i Vomiting. 





Figure 1. Structures of 5-hydroxytryptamine (serotonin), sumatriptan, and ergotamine. 
Sumatriptan is an example of a triptan, drugs that are used to treat migraines and 
ergotamine is a natural product that binds to the 5HTRs. Triptans bind to the 5HT1B and 
5HT1D receptors. The structure of serotonin (red) is seen in both sumatriptan and 
ergotamine. 
In humans, there are 7 serotonin receptor families composed of 15 serotonin 
receptor (5-HTR) subtypes1. The families are the 5-HT1 receptors to the 5-HT7 receptors. 
All of the receptors are G protein-coupled receptors (receptors that interact with G 
proteins2, which transmit signals from stimuli outside the cell to inside) except 5-HT3, 
which is a ligand-gated ion channel (membrane proteins that allow certain ions to cross the 
plasma membrane3). The 5-HT1A, 5-HT1B, and 5-HT1C receptors are located in the CNS 
and the blood vessels. Whereas the 5-HT1F receptor is located only in the CNS4. The 5-HT1 
and 5-HT5 receptors both negatively couple with adenylyl cyclase and when activated, they 
lower the level of cyclic adenosine monophosphate (cAMP)5. Through the Gq signaling 
pathway, the 5-HT2 receptors increase the amount of inositol triphosphate and 




AMP activity5. The 5-HT3 receptor is a sodium/potassium selective cation channel and 
causes depolarization of the plasma membrane5. 
The serotonin receptors have similar binding pockets because serotonin must be 
able to bind to them. These similarities can cause problems, like unforeseen side effects of 
a drug due to binding to a different receptor than the one it’s supposed to target. A well-
known example of this is Fen-Phen, fenfluramine-phentermine (Figure 2). Fen-Phen was 
designed to be an anti-obesity drug combination, that was supposed to cause appetite 
suppression from phentermine releasing norepinephrine into the body8. However, it was 
pulled from the market due to norfenfluramine (the metabolite of fenfluramine) activating 
the 5-HT2 receptors9, causing heart valve disease. 
 
Figure 2. Structures of fenfluramine (left) and phentermine (right), the two constituents of 
Fen-Phen, the anti-obesity drug combination. 
 The serotonin receptors are also selective as to what binds to them. When looking 
at the crystal structures of the 5-HT1B and 5-HT2B receptors (Figure 3), it can be seen that 
they are comprised of seven helices10,11. These helices interact with compounds that bind 
to the receptor. However, these two receptors have different active site conformations10. 
Which means that although they both have the same natural ligand, serotonin, another 
agonist for the 5-HT1B receptor might not be the best agonist for the 5-HT2B receptor. 
Where an agonist is a drug that binds and activates a receptor and an antagonist is a drug 




to synthesize drugs that will target individual receptors. Doing so will decrease the risk of 
side effects from the drugs binding to other receptors (like with Fen-Phen).  
 
Figure 3. The 3-D structures of 5-HT2B receptor (5TVN6) (left) and the 5-HT1B receptor 
(5V547) (right) as reported by the Protein Data Bank (PDB) 
Triptans 
Triptans are drugs that bind to a subset of serotonin receptors (5HT1B and 5HT1D) 
and are used to treat migraines12. It is believed that when triptans bind to the 5HT1B 
receptors, they cause vasoconstriction of the enflamed cranial arteries that occur during 
migraines and when they bind to the 5HT1D receptors they reduce pain13. Throughout the 
years, the synthesis of triptans has been optimized to increase the yield, the bioavailability 
(the amount of a drug that causes an effect once brought into the body), and better the 
pharmacokinetics (the movement of and any changes to a drug while in the body) (see 




Triptan Oral bioavailability (%) t1/2 (h) Year Released 
Sumatriptan 15 2 1995 
Zolmitriptan 40-48 2.5-3 1997 
Naratriptan 63-74 5-6.3 1998 
Rizatriptan 45 2-3 1998 
Almotriptan 80 3.2-3.7 2001 
Frovatriptan 24-30 25 2001 
Eletriptan 50 3.6-5.5 2002 
Table 1. The Pharmacokinetics of seven triptans along with the year they were released12 
The structure of triptans, as seen in Figure 4, all have the same tryptamine center, 
but they differ at the 3rd and 5th positions. These differences in structure are why each 
triptan interacts differently with the 5HTRs and has different pharmacokinetic properties 
(i.e. bioavailability). This is seen when comparing sumatriptan and almotriptan, they have 
the same 3rd position, but different 5th positions. Then when comparing their 
pharmacokinetic properties, sumatriptan is more bioavailable, has a shorter half-life, etc. 
than almotripitan. The same trend in bioavailability, half-life, etc. is seen with the other 
triptans. When the 5th or 3rd position varies, so do the pharmacokinetic properties. 
A future goal of this project is to attach an azobenzene to the 5th position on the 
indole intermediate. The hypothesis is that product produced from this will still retain its 
agonistic characteristics based on the structures of triptans. This is due to triptans retaining 
agonistic activity while containing various groups attached to the 5th position of the indole 
(i.e. donitriptan). Docking studies looked into this 5th position and the binding of triptans 
to the 5-HT1B and 5-HT2B receptors. The study found that triptans readily bound to the 5-
HT1B receptor but had to conform to unfavorable positions to bind to the 5-HT2B receptor11. 
This is due to the narrower V-shaped binding pocket in the 5-HT2B receptor11. The study’s 
results indicate that the wider V-shape of the 5-HT1B receptor is key to incorporate the 











Photopharmacology is a subset of pharmacology that uses light to control biological 
functions15. In this process, light is used to activate or deactivate a drug using moieties 
known as photoswitches. A photoswitch is a compound whose structure changes 
(photoisomerizes) with the application of light. There are a variety of photoswitches 
(Figure 5) that can be used for controlling biological functions, such as azobenzenes, 
diarylethenes, stilbenes, spiropyrans, thiophenefulgides, hemithioindigos, etc.  
 
Figure 5. Structures of some of the common photoswitches 
Azobenzenes undergo reversible cis-trans photoisomerization using UV-visible 




and it is not always reversible16. Spiropyrans undergo the cleavage of a C-O bond with 
irradiation using UV light to produce the merocyanine form16. This process is also 
reversible using light and heat. Diarylethenes also undergo reversible photoisomerization, 
however it is caused by light induced cyclization due to the presence of a hexatriene 
group16. These photoswitches are not thermally reversible. Thiophenefulgides are similar 
to diarylethenes in how they undergo reversible light induced cycliziation of the hexatriene 
group forming a cyclohexadiene ring16. Hemithioindigos undergo photoisomerization from 
the Z-E conformations of the olefinic bond16. These photoswitches undergo a variety of 
light driven reactions, such as double bond isomerization, 6 pi electrocyclization, etc. 
Azobenzenes are compounds composed of 2 benzene rings connected by a 
nitrogen-nitrogen double bond. They can be synthesized through azo coupling (Scheme 1), 
the Mills reaction (Scheme 2), the Wallach reaction (Scheme 3), etc17. In azo coupling, a 
primary amine is diazotized (becomes a diazonium salt) and undergoes an electrophilic 
substitution of an aromatic moiety17. In the Mills reaction an aniline attacks a nitroso-
aromatic moiety under acidic conditions to produce an azobenzene17. In the Wallach 
reaction, an azoxybenzene is converted into 2- or 4-hydroxy substituted azobenzene moiety 
under acidic conditons17. 
 





Equation 2. The Mills reaction of nitrosobenzene with an aniline to produce an azobenzene. 
 
Scheme 3. The Wallach reaction to produce 3 azobenzenes. 
These compounds are able to switch between cis and trans conformations using 
light (Figure 6). The formation of the cis isomer occurs with irradiation of approximately 
320 nm of light and the formation of the trans isomer occurs through either thermal 
relaxation or irradiation with approximately 460 nm of light16. However, the substitution 
on the benzenes can greatly change the wavelengths. The trans conformation is more stable 
than the cis due to steric interactions present in the cis conformation. This ability is valuable 
because it can be used for drug delivery17, to alter the properties of materials18, and to be 
used in polymers to release materials from micelles19. We predict that the azologizationiii 
of the indole intermediate is possible based on the structures of triptans. Ideally, the triptan 
 




derivative synthesized will bind to a serotonin receptor in either the trans- or cis- 
configuration, but not both (Figure 7), resulting in the photocontrol of the receptor. 
 
Figure 6. The structure of an azobenzene switching between the trans and cis 
conformations 
 
Figure 7. Schematic showing theoretical binding (left) and unbinding (right) of the 
photoswitch containing triptan derivative when it is exposed to UV light. 
Currently there has been the photocontrol of the 5-HT2C20 receptor (2013) and the 
5-HT321 receptor (2019). For the photocontrol of the 5-HT2C receptor, an optogenetic 
solution was created as a possible treatment for anxiety20. The optogenetic solution created 
was a melanopsin based probe to activate the Gq signals in the 5-HT2C receptor domains20. 
In the case of the 5-HT3 receptor, nine antagonists were reviewed, however only one kept 
its antagonistic activity while being a photoswitch21. The antagonist synthesized that kept 
its antagonistic activity (16c) can be seen in Scheme 4. The photoswitch used for this 




antagonistic is believed to be due to the potency of the starting structure for the synthesis 
of 16c.  
 
Scheme 4. The scheme for the synthesis of four of the 5-HT antagonists synthesized by 
Rustler et. al.21 where 16c is the only photoswitch that retained antagonistic activity. Where 
DIPEA is diisopropylethylamine. 
Motivation 
This research is pertinent because more than 264 million people worldwide have 
depression22, 1 billion people suffer from migraines23, about 10-15% of the population has 
IBS24, about 15 people per million people are diagnosed with PAH25, and as of 2017 there 
were 1,400 deaths in the US due to SIDS26. These are all serotonin related diseases that 
people currently suffer from. Researching the function of the different serotonin receptors 
is necessary for medical applications to be developed. Thus, the photocontrol of serotonin 
receptors could clarify their role in many important biological processes. 
The purpose of this project is to synthesize and photochemically characterize a 




will be done by synthesizing an indole compound with an aniline on the 5th position. Ideally 
this aniline would have to be replaced by an azobenzene and then exposed to UV light to 
test the optical and agonistic characteristics. However, due to complications during the first 
half of the synthesis and time constraints, this was unable to be completed. Despite this, 
the first two steps of the synthesis were completed, relatively pure product was collected 
(based on NMR), ideal column conditions were determined, and a plan for future work is 
proposed.  
 
Figure 8. The two targeted chemical structures that would have been synthesized in this 
project. Substitution of the R2 group can be varied to change the photochemical properties 






METHODS AND MATERIALS 
Reagents and Equipment 
 The solvents and reagents used in the synthesis of the indole intermediate are 5-
nitroindole, phthalimide, oxalyl chloride, diethylamine, dimethylamine, borane 
tetrahydrofuran, hydrogen, palladium on carbon, and magnesium sulfate (used for drying) 
purchased from Sigma Aldrich and Fischer Chemicals. The solvents used in the reactions, 
work ups, and purification include acetone, dichloromethane, diethyl ether, triethylamine, 
methanol, sodium bicarbonate, hydrochloric acid, hexanes, DI water (from local system), 
deuterated acetone, deuterated chloroform, and deuterated methanol purchased from Sigma 
Aldrich and Fischer Chemicals. 
 The equipment used for the synthesis of the indole intermediate include Heidolph 
Heizbad Hel-VAP rotary evaporator, a Yamato rotary evaporator, a Mettler Toledo 
balance, a Sartorius balance, a Chemglass Life Sciences AREX 6 Digital Pro hot and stir 
plate, a Fisher hot and stir plate, and a Bruker 500-megahertz (MHz) nuclear magnetic 










Scheme 5. The reaction scheme for the synthesis of the indole intermediate, 4, based on a 
published route27. Reagents: i. oxalyl chloride, diethyl ether, phthalimide, rt, 72 h. ii. 
diethylamine or dimethylamine, diethyl ether, 0 ℃, 1 h. iii. BH3-THF, rt, 16 h, CsF, 
Na2CO3, reflux, 16 h. iv. H2, Pd/C, ethanol, rt, 6 h. 
 The reaction scheme for the synthesis of the indole intermediate can be seen in 
Scheme 5. The production of compound two was successfully completed for both the 
diethylamine and dimethylamine reactions. The reduction of the carbonyls on compound 
2 to product compound 3 was attempted once. The specific reactions are listed in the 
following sections. 
Synthesis of Indole Intermediate with diethylamine 
 




 5-nitroindole 30.9 mg (0.1906 mmol) was added to a 25 mL pear flask. Next, 2 mL 
of diethyl ether were added to the pear flask. The flask was then flushed with nitrogen and 
then 0.11 mL (1.28 mmol) of oxalyl chloride was added to the flask. The contents were 
stirred for 72 hours at room temperature. Reaction progress was monitored using TLC 
using 10% acetone in DCM, 5% methanol in DCM, and 5% methanol in DCM with 
triethylamine. After 72 hours, 1 mL of diethyl ether was added to the flask. The reaction 
was then placed in an ice bath and flushed with nitrogen while 0.18 mL (1.74 mmol) of 
diethylamine were added. The reaction was stirred at 0 ℃ overnight. The resulting yellow 
mixture was extracted using DCM and water three times. The reaction was then washed 
with ethyl acetate and water three times. The reaction underwent column chromatography 
in 5% methanol in DCM with triethylamine. The fractions were collected and NMR was 
run in deuterated methanol. The reaction was then washed three times with sodium 
bicarbonate and then washed with brine three times. The solution was concentrated in a 
rotary evaporator and high vac to produce a yellow/orange solid with 72.9% yield. A 
second NMR was taken in deuterated acetone. 
  In the following reactions, the sodium bicarbonate wash was done during the work 
up along with drying using magnesium sulfate. Also, residual amine was present in liquid 
form in collected product after purification using column chromatography. To remove this, 
the product was concentrated on the rotary evaporator for a longer period of time or the 
product was left on high vacuum. However, high vacuum caused product degradation, 
resulting in the discontinuation of that method. This was seen in the H1 NMR taken before 
and after high vacuum of a sample. There were unknown aromatic impurities seen in the 




high vacuum, the integrations of the impurities had increased to approximately 0.4 (Figure 
10), indicating that the product had degraded. 
 
Figure 9. Zoomed in H1 NMR of aromatic region of diethylamine reaction before being 





Figure 10. Zoomed in H1 NMR of aromatic region of diethylamine reaction after being 
high vacuumed to remove excess amine. The unknown aromatic impurities are highlighted. 
Rf – 0.14, 5% methanol in DCM with triethylamine, UV light 
1H NMR (500 MHz, Acetone-d6) δ 9.16 (d, J= 2 Hz, 1H), 8.34 (s, 1H), 8.19 (dd, Js= 2.5 
Hziv, Jl= 9 Hzv, 1H), 7.80 (dd, Js= 0.5 Hz, Jl= 9 Hz, 1H), 3.52 (q, J=7.2 Hz, 2H), 3.39 (q, 
J=7.2 Hz, 2H), 1.24 (t, J= 7.5 Hz, 3H), 1.18 (t, J= 7 Hz, 3H). 
12C NMR (500 MHz, Acetone-d6) δ 186.68, 166.54, 143.85, 140.09, 139.12, 125.04, 
118.87, 117.77, 115.36, 113.06, 41.99, 38.67, 13.80, 12.21. 
 
 
iv Js is the average J value determined for the peaks that are closest together in the doublet of doublets 




Synthesis of Indole Intermediate with dimethylamine 
 
Scheme 7. Dimethylamine reaction to produce compound 2. 
 5-nitroindole 107.2 mg (0.6611 mmol) was added to a 25 mL pear flask. Next, 
341.4 mg (1.84 mmol) of phthalimide and 8 mL of diethyl ether were added to the pear 
flask. The flask was then flushed with nitrogen and then 0.15 mL (1.749 mmol) of oxalyl 
chloride was added to the flask. The contents were stirred for 72 hours at room temperature. 
Reaction progress was monitored using TLC using 10% acetone in DCM. After 72 hours, 
8 mL of diethyl ether was added to the flask. The reaction was then placed in an ice bath 
and flushed with nitrogen while 0.3 mL (4.47 mmol) of diethylamine were added. The 
reaction was stirred at 0 ℃ for 1 hour. The resulting yellow mixture was extracted using 
DCM and water three times. pH adjustment was not needed, because the reaction was 
already at pH 3. The reaction was then washed with a 0.6 M sodium bicarbonate solution 
three times. The liquid solution was dried using MgSO4 and concentrated in a rotary 
evaporator to produce a crude, yellow/orange solid. Column chromatography was not run 
on this dimethylamine reaction or the following dimethylamine reactions. Column 
chromatography was run on the two previous dimethylamine reactions in 5% acetone in 




1H NMR (500 MHz, Acetone-d6) δ 9.22 (d, J= 2 Hz, 1H), 8.10 (d, J= 2.5 Hz, 1H), 7.56 (q, 
J= 4.7 Hz, 1H), 7.36 (s, 1H), 3.64 (s, 3H), 3.19 (s, 3H). 
Reduction 
 
Scheme 8. Reduction of compound 2 to compound 3. 
 Compound 2 (28.6 mg, 0.098 mmol) was transferred to a round bottom flask and 
placed under nitrogen. To this, 1.5 mL of borane tetrahydrofuran (1.5 mmol) was added. 
The reaction was stirred at room temperature for 16 hours. After 16 hours, the reaction was 
extracted in sodium bicarbonate and ether. The liquid solution was concentrated in a rotary 
evaporator. Reaction was checked using TLC in 5% acetone in DCM. 1H NMR was taken 
on the product in deuterated acetone. Column chromatography was done in 5% acetone in 
DCM. Fractions were concentrated in a rotary evaporator. This reaction did not work, as 
seen in the NMR (Appendix). Also, during this time reaction conditions were still being 
worked out. 






RESULTS, DISCUSSION, CONCLUSION, & FUTURE WORK 
Results & Discussion 
 
Scheme 9. Proposed mechanism for the formation of the dimethylamine moiety  
 A plausible mechanism (Scheme 9) for the first two steps in the synthesis of the 
indole intermediate (Scheme 5) is seen above. The nitrogen on the indole acts as an 
enamine and pushes electrons to the 3rd position carbon. This carbon then acts as the 
nucleophile and attacks the C-O bond in oxalyl chloride forming a tetrahedral intermediate. 




Phthalimide deprotonates the hydrogen at the 3rd position, reforming the double bond and 
pushing the electrons back onto the nitrogen. Then the lone electrons on the amine attack 
the other C-O bond forming another tetrahedral intermediate. The electrons on the oxygen 
again push down, reforming the carbonyl and pushing off chlorine as the leaving group. 
The proton on the nitrogen is removed by phthalimide. 
Diethylamine and dimethylamine reactions to produce compound 2 
 
Figure 11. Compound 2 
 For the diethylamine reaction (Scheme 6) and dimethylamine reaction (Scheme 7), 
the desired product was compound two (Figure 11). This compound was successfully 
produced and isolated in one diethylamine reaction, but failed to be isolated again in future 
reactions. The difficulties lied in separation of impurities using column chromatography. 
The column chromatography conditions for the first reaction were 5% methanol in DCM 
with triethylamine which was then increased to 10% methanol in DCM. Column 
chromatography conditions were varied throughout the experiments in hopes to get the best 
separation. One solvent system used for another diethylamine reaction was 5% acetone in 
DCM that was increased to 11% acetone in DCM. Triethylamine was also added to the 5% 
acetone in DCM system in an attempt to make the column run faster. It was believed that 
by increasing the polarity of the solvent system, then the separation would be better. 




this solvent system seemed to be too polar since good separation was not achieved. The 
poor separation had to do with amine streaking throughout the column. There would 
continuously be excess amine present throughout the collected fractions (Figure 12). 
Another difficulty in separation is that the product would often stick to the column, 
resulting in the polarity continuously being increased. In a later reaction, a less polar 
solvent system was used in an attempt to improve separation in comparison to the last 
system. This solvent system started with 100% DCM and was increased to 10% acetone in 
DCM. A large amount of color was observed coming off the column during the switch 
from 5% to 10% acetone in DCM, indicating that an incremental increase should be done 
in the future. The solvent systems used in column chromatography were tested using TLC 
to see which yielded the best separation. The polarity of the solvent systems was increased 
in an attempt to move the product spot off of the baseline. 
 
Figure 12. Vial containing product collected from a diethylamine reaction. The collected 




 Another difficulty while purifying the reactions is the production of a yellow solid 
during the DCM/DI water extractions (Figure 13). This solid would start off in the organic 
layer, as can be seen in the figure, but would move to the aqueous layer once the pH was 
adjusted to 3 and the separatory funnel was shook. It remained a solid in the aqueous layer, 
indicating that it was insoluble in both phases. However, once it was in the aqueous layer 
it was discarded as waste. The solid was neither verified to be product or waste. 
 
Figure 13. Image of a separatory funnel containing product being extracted in DCM and 
DI Water. 
 For both the diethylamine and dimethylamine experiments, reaction conditions 
were varied in hopes of optimizing the reaction yield. A summary of these conditions can 




of product collected, the amount of starting material (5-nitroindole) was increased. The 
first few diethylamine and dimethylamine reactions used 30-40 mg of 5-nitroindole. This 
was increased to 100 mg to increase the yield of the reactions. Dimethylamine was used 
because it was the reported reagent used in the literature27. Diethylamine was used in this 
experiment to vary the groups on the third position of the indole. For the majority of the 
reactions, the equivalencies used for oxalyl chloride and amine followed the reported 
equivalencies (approximately 3 and 9 equivalencies respectively). These were changed for 
the last three reactions due to very little product being produced, indicated by the low 
intensity of the product peak in 1H NMR, and multiple unknown peaks showing up in 1H 
NMR. At first just the equivalency of oxalyl chloride was increased because it was a 
plausible point of failure in the reaction due to the instability of the reagent over time and 
the age of the reagent bottle. The equivalency was increased by a factor of four to 12 
equivalencies, while keeping all of the other reagents the same. This was because the first 
step of the reaction was not being completed which was indicated by unreacted starting 
material present in H1 NMR (Figure 14). By increasing the amount of oxalyl chloride in 
the reaction, then more starting material would be reacted with to produce more product. 
However, it was realized that product wouldn’t be produced if there wasn’t enough amine 
present in the reaction to react with the oxalyl chloride. To fix this, the stoichiometry of 
phthalimide and amine were increased by a factor of four, while keeping starting material 
the same. The crude 1H NMRs for all three of these reactions indicated the presence of 
product due to a product peak around 9 ppm. An example of the peak around 9 ppm can be 





Table 2. A summary of the reaction conditions for the various reactions ran.  
 
 
Figure 14. Zoomed in aromatic region in 1H NMR of crude dimethylamine reaction 



















CS1-4 30, 1 - 3.1 2 1-1.5 - 9.3 -
CS1-9 30, 1 - 3.1 2 1-1.5 - 12.4 -
CS1-35 100, 1 3 3.1 5 2.5-3.75 - 9 -
CS1-42 100, 1 3 3.1 10 3 - 9 -
CS1-54 100, 1 3 3.1 8 8 - 9 41.15
CS1-63 100, 1 3 3.1 8 5 - 9 -
CS1-73 100, 1 12 12 10 5 - 36 5.51
CS1-19 30, 1 - 3.1 2 1-1.5 9.3 - -
CS1-29 40, 1 2.8 3.1 2 1-1.5 9.3 - -
CS1-60 100, 1 3 3.1 8 8 9 - 11.71
CS1-68 100, 1 3 12 10 6 9 - -





Figure 15. Zoomed in NMR of the diethylamine reaction to produce compound 2. The peak 




Reduction of compound 2 to compound 3. 
 
Scheme 10. The proposed mechanism for the diethylamine reduction of compound 2 to the 
borane-amine complex. This complex is further reacted with CsF and Na2CO3 to 
decompose the complex. 
 The proposed mechanism for the diethylamine reduction of compound 2 to 
compound 3 is seen in scheme 10. Borane reacts with one of the carbonyls to form a boron-
oxygen bond and a carbon-hydrogen bond. Another equivalent of borane is required to 
react with the oxygen again and remove it and to give the carbon another hydrogen. This 
same process is repeated on the second carbonyl to produce compound 3.  
For this reaction, borane tetrahydrofuran was added directly to compound 2 and 
then was worked up. However, the literature shows that a tryptamine-borane complex is 
formed once borane tetrahydrofuran is added to compound 227. The literature used cesium 




would be done for future reactions. 1H NMR was taken on the product in deuterated 
acetone. The NMR lacks the identifying peaks in the aromatic region for the production of 
compound 3, indicating that the reaction did not work (Figure 16). One of these key peaks 
would be a doublet at approximately 9 ppm. However, the spectrum below only shows one 
singlet at 8.14 ppm and two quartets around 7.70 ppm. Neither of these indicate the 
formation of product. 
 






 Based on the 13C and 1H NMR spectra the first two steps of the synthesis of the 
indole intermediate were completed and product was produced with 72.9% yield. The 
column conditions that provided the best separation was determined to be 5% methanol in 
DCM with triethylamine, used in the diethylamine reaction to produce compound 2. The 
product isolated from this reaction seemed to have to cleanest NMR spectra. The reaction 
stopped working due to the age and instability of the reagents. The difficulty with the 
separation/purification steps was due to the solvent system being changed from the one 
used initially. 
Future Work 
 Future work would be to finish this synthesis (Scheme 11), purify the product, and 
run 13C and 1H NMR and HRMS. To finish the synthesis, the reduction of the carbonyls 
on compound 2 using borane tetrahydrofuran, cesium fluoride, sodium carbonate, and an 
ethanol reflux to afford compound 3 needs to be performed. Then the reduction of the nitro 
group on compound 3 to afford compound 4 (indole intermediate) using hydrogen and 
palladium on carbon. Then azologization of the indole intermediate would be done through 
the Mills reaction seen in Scheme 12 or through the reaction seen in Scheme 13. In the 
Mills reaction, nitrosobenzene (commercially available) will be reacted with the indole 
intermediate to produce the first azo product. In the second reaction, 4-Phenylazobenzoic 
acid (commercially available) reacts with thionyl chloride to produce the azobenzene 
moiety that will react with the indole intermediate to produce the second azo product. 
Various substitutions could be induced onto the benzene rings to change the properties of 
the compounds. These products would be purified and their photochemical properties need 




that the cis/trans isomers interconvert with light. The best wavelengths for photoswitching, 
the wavelengths that have the highest conversion between isomers, needs to be determined, 
along with the thermal relaxation for the cis isomer to the trans isomer in aqueous solution. 
13C and 1H NMR and HRMS would also be run on the products. The agonistic properties 
of the products would then be tested on serotonin receptors. This would be done by 
purchasing cell culture assays with cells that express the 5-HT1B and 5-HT1D receptors. For 
example, Chinese hamster ovary (CHO) cell assays are commonly used for biochemical 
research.  
 
Scheme 11. The reduction of compound 2 to compound 3, followed by the reduction of the 
nitro group on compound 3 to produce compound 4 (indole intermediate). 
 
Scheme 12. The Mills reaction to attach the azobenzene to the indole intermediate17. Where 





Scheme 13. The second reaction to attach an azobenzene to the indole intermediate21. 
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Figure 17. 1H NMR (500 MHz, Acetone-d6) spectrum for the first diethylamine reaction to 





Figure 18. 12C NMR (500 MHz, Acetone-d6) spectrum for the first diethylamine reaction 





Figure 19. 1H NMR (500 MHz, CDCl3) spectrum for a later diethylamine reaction to 






Figure 20. Crude 1H NMR (500 MHz, CDCl3) spectrum for a dimethylamine reaction to 






Figure 21. Crude 1H NMR (500 MHz, CDCl3) spectrum for a dimethylamine reaction to 






Figure 22. Crude 1H NMR (500 MHz, CDCl3) spectrum for the last diethylamine reaction 






Figure 23. 1H NMR (500 MHz, Acetone-d6) spectrum for the reduction reaction of 







 Chelsea M Sainsbury was born in Danbury, Connecticut on October 16th, 1999. She 
was raised in Watertown, Connecticut and graduated from Watertown High School in 
2017. Chelsea is majoring in chemistry. 
 After graduating, Chelsea will be working towards a PhD in chemistry at the 
University of Washington. 
 
